Lilly (LLY.US) recommends Elpida peptide as a weight loss drug by the UK regulatory agency.
The UK's National Institute for Health and Care Excellence has officially recommended the GLP-1 drug Tirzepatide from Lilly as a weight loss medication.
The UK's drug cost-effectiveness watchdog, the National Institute for Health and Care Excellence (NICE), has formally recommended Eli Lilly and Company's GLP-1 drug Tirzepatide as a weight loss medication. The drug is sold under the names Zepbound for weight loss and Moujaro for treating type 2 diabetes.
Due to anticipated high demand, NICE had earlier stated in December that Tirzepatide would be rolled out over a three-year period, with the "highest clinical need" patients being given priority for the drug.
Related Articles
CHINAHONGQIAO (01378) cancelled 300,000 repurchased shares on October 23rd.
Responding to the manufacturing industry reshoring trend, Apple Inc. (AAPL.US) has shipped its first batch of "Made in America" AI servers from Texas.
RSUN SER(01971): The obligor claims to have taken action to enforce the pledgee's rights in the pledged shares.
CHINAHONGQIAO (01378) cancelled 300,000 repurchased shares on October 23rd.
Responding to the manufacturing industry reshoring trend, Apple Inc. (AAPL.US) has shipped its first batch of "Made in America" AI servers from Texas.
RSUN SER(01971): The obligor claims to have taken action to enforce the pledgee's rights in the pledged shares.
RECOMMEND
Why European Automakers Are Opposing Dutch Sanctions
20/10/2025
Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025
Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025
